Sight to behold: Japan´s Menicon launches Myopia Control Management System
KUALA LUMPUR, May 24 (Bernama) -- Menicon Co Ltd, Japan's first and largest contact lens manufacturer today launched the Menicon Bloom Myopia Control Management System, a holistic approach for myopia control management.
Myopia, also known as near or short-sightedness, is the most common refractive error and the major cause of vision impairment worldwide.
The launch features the initial introduction of Menicon Bloom Night, an orthokeratology contact lens therapy for myopia control management.
Menicon Bloom Night therapy involves the overnight wear of a specially-designed reverse geometry orthokeratology contact lens.
The treatment temporarily changes the shape of the cornea, which results in reduction of refractive error, thus eliminating the need to wear contact lenses throughout the waking hours after lenses are removed.
The contact lenses have been reviewed and validated via numerous comprehensive, peer-reviewed studies related to myopia control management.
With the accumulation of long-term and comprehensive scientific evidence over the years, Menicon Bloom Night has met the highest standards of safety, efficacy and quality required to grant the treatment CE approval for myopia control management in Europe.
The treatment will be launched initially in The Netherlands, followed soon thereafter with launches in other European markets.
Further information on the product and availability will be forthcoming. More details at http://www.menicon.com
-- BERNAMA
Myopia, also known as near or short-sightedness, is the most common refractive error and the major cause of vision impairment worldwide.
The launch features the initial introduction of Menicon Bloom Night, an orthokeratology contact lens therapy for myopia control management.
Menicon Bloom Night therapy involves the overnight wear of a specially-designed reverse geometry orthokeratology contact lens.
The treatment temporarily changes the shape of the cornea, which results in reduction of refractive error, thus eliminating the need to wear contact lenses throughout the waking hours after lenses are removed.
The contact lenses have been reviewed and validated via numerous comprehensive, peer-reviewed studies related to myopia control management.
With the accumulation of long-term and comprehensive scientific evidence over the years, Menicon Bloom Night has met the highest standards of safety, efficacy and quality required to grant the treatment CE approval for myopia control management in Europe.
The treatment will be launched initially in The Netherlands, followed soon thereafter with launches in other European markets.
Further information on the product and availability will be forthcoming. More details at http://www.menicon.com
-- BERNAMA
Comments
Post a Comment